---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-019754"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:14:20.672105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences reports Q4/FY2023 net loss; $487M pro-forma cash; bezuclastinib trials on track

## Summary
- Q4 2023 net loss $54.4M; FY2023 net loss $192.4M (up from $140.2M YoY); R&D expenses $173.8M for 2023.
- Cash $273.2M at Dec 31, 2023; $225M PIPE closed Feb 2024 at $7.50/share (37% premium); pro-forma $487M funds into 2027.
- Three registration-directed bezuclastinib trials enrolling: SUMMIT (NonAdvSM), APEX (AdvSM), PEAK (GIST); topline results expected in 2025.
- SUMMIT Part 1b data: 51% mean TSS improvement, 70% of patients with ≥50% improvement; 100 mg RP2D selected.
- PEAK lead-in: 33% confirmed ORR in 2nd-line GIST; bezuclastinib+sunitinib combination well-tolerated.

## SEC filing metadata
- accession: 0000950170-24-019754
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/0000950170-24-019754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/cogt-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-019754
- JSON: https://secwatch.observer/filing/0000950170-24-019754.json
- Plain text: https://secwatch.observer/filing/0000950170-24-019754.txt

## Key facts
- Earnings Releases
  Cogent Biosciences, Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 26, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/0000950170-24-019754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.